ASSORTMENT-COMPENSATION CHARACTERISTICS OF SIMVASTATIN AS A MEANS OF PREVENTION OF ACUTE DISORDERS OF CEREBRAL BLOOD CIRCULATION IN REGISTERS OF GOVERNMENTAL PROGRAM “AFFORDABLE DRUGS”
DOI:
https://doi.org/10.11603/2312-0967.2020.1.10970Keywords:
acute disorders of cerebral blood circulation, simvastatin, trade name, governmental program, reimbursementAbstract
The aim of the work. Research of the dynamics of trade names (TN) of simvastatin, which are included in the registers of the governmental program "Affordable drugs" (hereinafter referred to as "Registers"), from the point of view of the range and the share of their reimbursement to the patient.
Materials and Methods. Research materials – information from eight Registers of 2017–2020 on the reimbursement of simvastatin TN cost. Methods: information search, analysis and generalization.
Results and Discussion. It has been established that the Registry included from 4 to 16 TNs of simvastatin, taking into account different dosages. The dynamics of wholesale prices and retail prices (RP) for the packaging of simvastatin TN testify to them being decreased during the analyzed period. The price change index for 93.8 % of the analyzed TNs (taking into account different dosages), was less than 1 and was within 0.52… 0.98. The results of the analysis of the dynamics of the share of the compensation of the simvastatin TN value and the consumer surcharge showed that 90… 100 % reimbursement of the cost was declared in the first and second registers for all TNs with different dosages, in the third – 60… 100 %, in the other registers – 50… 100 % of the cost of drugs. A comparative situational analysis of RP on simvastatin TNs with different dosages in 176 pharmacies in Lviv and in the eighth Register showed that its minimum rate in pharmacies was lower than in the Register, and the maximum – for 61.5 % of TNs was lower or equal to the price in the Register. Only for 5 TNs RP in pharmacies was higher than in the Register.
Conclusions. It has been established that the range of simvastatin TNs (taking into account different dosages) has increased fourfold since the launch of the governmental program “Affordable drugs”. It has been found that the number of simvastatin TNs with full compensation increased from 25 % in the first to 56.3 % in the eighth Register, which indicates an increase in the affordability of simvastatin for patients with acute disorders of cerebral blood circulation. Low flexibility in compliance with RP in pharmacies in Lviv and in the eighth Register has been established, which, in our opinion, can be explained by a significant time delay between the administrative decision making on the value of RP for simvastine and its market change.
References
Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. Presse Med. 2016;45(12 Pt 2): e391-8. doi: 10.1016/j.lpm.2016.10.003. Epub 2016 Nov 2. DOI: https://doi.org/10.1016/j.lpm.2016.10.003
Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA. Statins in stroke prevention: Present and future. Curr Pharm Des. 2016;22(30): 4638-44. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27160755 DOI: https://doi.org/10.2174/1381612822666160510125229
Order of the Ministry of Health of Ukraine “On approval and implementation of medical and technological documents on standardization of medical care for hemorrhagic stroke. Spontaneous intracerebral hemorrhage. Adapted clinical guideline based on evidence” from April 17, 2014, No. 275. [Electronic resource]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2716075 [Accessed March 2020]. Ukrainian.
Bezditko NV. Pharmacoepidemiological analysis: dynamics of availability of statins in Ukraine. Klinichna farmats. 2016;20(2): 6-11. DOI: https://doi.org/10.24959/cphj.16.1383
Ievtushenko OM, Nemtsova VD, Tchaikovska VV. [Statins: pharmacoeconomic aspects of the use of HMG-CoA reductase inhibitors]. Klinichna farmats. 2019;23(1): 46-55. Ukrainian. DOI: https://doi.org/10.24959/cphj.19.1476
Order of the Ministry of Health of Ukraine “On approval of the Register of Medicinal Products to be reimbursed as of 03 April 2017” from April, 2017 No. 360. [Electronic resource]. Available from: https://zakon.rada.gov.ua/rada/show/v0360282-17/ed20170414. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On amendments to the Register of Medicinal Products, the cost of which is to be reimbursed” from April, 2017 No. 436. [Electronic resource]. Available from: https://www.apteka.ua/article/408393. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On approval of the Register of Medicinal Products to be reimbursed as of July 26, 2017” from July, 2017 No. 856. [Electronic resource]. Available from: https://www.apteka.ua/article/420532. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On approval of the Register of Medicinal Products to be reimbursed as of 22 January 2018” from January, 2018 No. 111. [Electronic resource]. Available from: https://moz.gov.ua/uploads/0/3077-dn_20180122_111_dod.pdf. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On approval of the Register of Medicinal Products to be reimbursed as of 23 July 2018” from July, 2018 No. 1367. [Electronic resource]. Available from: https://moz.gov.ua/uploads/1/6148-dn_20180723_1367_dod.pdf. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On approval of the Register of Medicinal Products to be reimbursed as of 21January 2019» from January, 2019 No. 148. [Electronic resource]. Available from: https://moz.gov.ua/uploads/1/9837-dn_20190121_148_dod.pdf. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On approval of the Register of Medicinal Products to be reimbursed as of 29 July 2019” from July, 2019 No. 1715. [Electronic resource]. Available from: https://moz.gov.ua/uploads/2/13734-dn_20190730_1715_dod.pdf. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On the amendments to the Register of Medicinal Products to be reimbursed as of 29 July 2019” from August, 2019 No. 1805. [Electronic resource]. Available from: https://moz.gov.ua/uploads/2/14039-dn_20190815_1805_dod.pdf. [Accessed March 2020]. Ukrainian.
Order of the Ministry of Health of Ukraine “On approval of the Register of Medicinal Products to be reimbursed as of 07 February 2020” from February, 2019 No. 316. [Electronic resource]. Available from: https://moz.gov.ua/uploads/3/18814-dn_20200213_316_dod.pdf. [Accessed March 2020]. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
